Merck Serono Backs Ambrx

Ambrx Inc., a La Jolla, Calif.-based developer of genetically-engineered protein therapeutics, has raised $10 million in new equity funding from Merck Serono SA, as part of a strategic collaboration agreement. peHUB had previously reported on the funding, based on a regulatory filing, but was unable to identify the source. Ambrx previously raised around $70 million from firms like 5AM Ventures, Aravis Ventures, CMEA Capital, Maverick Capital, Versant Ventures and Tavistock Life Sciences.